Spero Therapeutics (NASDAQ:SPRO) Cut to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Spero Therapeutics (NASDAQ:SPRO) from a buy rating to a hold rating in a report published on Friday, Zacks.com reports.

According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

Several other brokerages also recently commented on SPRO. HC Wainwright reaffirmed a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a research note on Monday, August 12th. TheStreet downgraded Spero Therapeutics from a c- rating to a d+ rating in a research note on Monday, July 29th. ValuEngine raised Spero Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $27.00 price objective on shares of Spero Therapeutics in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $20.60.

SPRO stock opened at $10.14 on Friday. The business’s fifty day moving average is $10.37 and its 200-day moving average is $11.54. The company has a quick ratio of 17.48, a current ratio of 13.66 and a debt-to-equity ratio of 0.04. The company has a market cap of $178.54 million, a P/E ratio of -3.90 and a beta of 2.08. Spero Therapeutics has a twelve month low of $5.52 and a twelve month high of $14.48.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.10). The company had revenue of $2.16 million during the quarter, compared to analyst estimates of $6.95 million. Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. Research analysts anticipate that Spero Therapeutics will post -2.94 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in Spero Therapeutics by 5.7% during the 4th quarter. BlackRock Inc. now owns 393,630 shares of the company’s stock worth $2,421,000 after buying an additional 21,161 shares during the period. Virtu Financial LLC acquired a new stake in Spero Therapeutics during the 1st quarter worth $134,000. Northern Trust Corp raised its stake in Spero Therapeutics by 1.1% during the 4th quarter. Northern Trust Corp now owns 96,833 shares of the company’s stock worth $595,000 after buying an additional 1,038 shares during the period. Bank of New York Mellon Corp raised its stake in Spero Therapeutics by 31.9% during the 4th quarter. Bank of New York Mellon Corp now owns 36,716 shares of the company’s stock worth $226,000 after buying an additional 8,888 shares during the period. Finally, Geode Capital Management LLC raised its stake in Spero Therapeutics by 4.4% during the 4th quarter. Geode Capital Management LLC now owns 91,842 shares of the company’s stock worth $564,000 after buying an additional 3,876 shares during the period. 46.75% of the stock is currently owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

See Also: How interest rates affect municipal bond prices

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Frontier Communications   Shares Down 7.3%
Frontier Communications Shares Down 7.3%
Seagate Technology   Shares Down 6.7%
Seagate Technology Shares Down 6.7%
Bruker Co.  Shares Bought by D. E. Shaw & Co. Inc.
Bruker Co. Shares Bought by D. E. Shaw & Co. Inc.
D. E. Shaw & Co. Inc. Lowers Stake in Aramark
D. E. Shaw & Co. Inc. Lowers Stake in Aramark
Synopsys, Inc.  Holdings Trimmed by D. E. Shaw & Co. Inc.
Synopsys, Inc. Holdings Trimmed by D. E. Shaw & Co. Inc.
Cadence Design Systems Inc  Stock Holdings Lifted by D. E. Shaw & Co. Inc.
Cadence Design Systems Inc Stock Holdings Lifted by D. E. Shaw & Co. Inc.


© 2006-2019 Ticker Report